American Association for Cancer Research
10780432ccr130774-sup-table_4.pdf (190.14 kB)

Supplementary Table 4 from Cumulative Genetic Risk Predicts Platinum/Taxane-Induced Neurotoxicity

Download (190.14 kB)
journal contribution
posted on 2023-03-31, 17:32 authored by Sarah McWhinney-Glass, Stacey J. Winham, Daniel L. Hertz, Jane Yen Revollo, Jim Paul, Yijing He, Robert Brown, Alison A. Motsinger-Reif, Howard L. McLeod

PDF file, 190K, Results of the 69 significant SNPs in the discovery cohort, for both the discovery and replication set. Covariates ECOG performance status, treatment status, time to first toxicity, and grade of GI toxicity.



Purpose: The combination of a platinum and taxane are standard of care for many cancers, but the utility is often limited due to debilitating neurotoxicity. We examined whether single-nucleotide polymorphisms (SNP) from annotated candidate genes will identify genetic risk for chemotherapy-induced neurotoxicity.Patients and Methods: A candidate–gene association study was conducted to validate the relevance of 1,261 SNPs within 60 candidate genes in 404 ovarian cancer patients receiving platinum/taxane chemotherapy on the SCOTROC1 trial. Statistically significant variants were then assessed for replication in a separate 404 patient replication cohort from SCOTROC1.Results: Significant associations with chemotherapy-induced neurotoxicity were identified and replicated for four SNPs in SOX10, BCL2, OPRM1, and TRPV1. The population attributable risk for each of the four SNPs ranged from 5% to 35%, with a cumulative risk of 62%. According to the multiplicative model, the odds of developing neurotoxicity increase by a factor of 1.64 for every risk genotype. Patients possessing three risk variants have an estimated OR of 4.49 (2.36–8.54) compared to individuals with 0 risk variants. Neither the four SNPs nor the risk score were associated with progression-free survival or overall survival.Conclusions: This study shows that SNPs in four genes have a significant cumulative association with increased risk for the development of chemotherapy-induced neurotoxicity, independent of patient survival. Clin Cancer Res; 19(20); 5769–76. ©2013 AACR.

Usage metrics

    Clinical Cancer Research



    Ref. manager